AU2008234374B2 - Method of determining risk of scoliosis - Google Patents

Method of determining risk of scoliosis Download PDF

Info

Publication number
AU2008234374B2
AU2008234374B2 AU2008234374A AU2008234374A AU2008234374B2 AU 2008234374 B2 AU2008234374 B2 AU 2008234374B2 AU 2008234374 A AU2008234374 A AU 2008234374A AU 2008234374 A AU2008234374 A AU 2008234374A AU 2008234374 B2 AU2008234374 B2 AU 2008234374B2
Authority
AU
Australia
Prior art keywords
scoliosis
opn
subject
expression
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008234374A
Other languages
English (en)
Other versions
AU2008234374A1 (en
Inventor
Alain Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire Sainte-Justine
Original Assignee
Centre Hospitalier Universitaire Sainte-Justine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire Sainte-Justine filed Critical Centre Hospitalier Universitaire Sainte-Justine
Publication of AU2008234374A1 publication Critical patent/AU2008234374A1/en
Application granted granted Critical
Publication of AU2008234374B2 publication Critical patent/AU2008234374B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
    • A61F5/01—Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
    • A61F5/0102—Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces specially adapted for correcting deformities of the limbs or for supporting them; Ortheses, e.g. with articulations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nursing (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
AU2008234374A 2007-03-30 2008-03-31 Method of determining risk of scoliosis Ceased AU2008234374B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90940807P 2007-03-30 2007-03-30
US60/909,408 2007-03-30
US2557108P 2008-02-01 2008-02-01
US61/025,571 2008-02-01
PCT/CA2008/000595 WO2008119170A1 (en) 2007-03-30 2008-03-31 Method of determining risk of scoliosis

Publications (2)

Publication Number Publication Date
AU2008234374A1 AU2008234374A1 (en) 2008-10-09
AU2008234374B2 true AU2008234374B2 (en) 2013-05-23

Family

ID=39807753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008234374A Ceased AU2008234374B2 (en) 2007-03-30 2008-03-31 Method of determining risk of scoliosis

Country Status (10)

Country Link
US (3) US20100075333A1 (enExample)
EP (1) EP2132568B1 (enExample)
JP (1) JP5426530B2 (enExample)
KR (1) KR101436578B1 (enExample)
CN (1) CN101680887B (enExample)
AU (1) AU2008234374B2 (enExample)
CA (1) CA2682114C (enExample)
IL (1) IL201186A (enExample)
MX (1) MX2009010400A (enExample)
WO (1) WO2008119170A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598875B1 (en) * 2010-10-04 2016-12-07 Chu Sainte-Justine Biomechanical-based methods of diagnosing scoliosis
DE102012102338A1 (de) 2012-03-20 2013-09-26 Hauni Maschinenbau Ag Messanordnung zum Messen von in Strangmaschinen der Tabak verarbeitenden Industrie hergestellten und geförderten Strängen
KR20210073616A (ko) 2012-08-09 2021-06-18 셀진 코포레이션 면역-관련 및 염증성 질환의 치료
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
KR20160020553A (ko) * 2013-06-17 2016-02-23 슈 생-쥐스땡 특발성 척추측만증의 심각한 진행에 대한 새로운 마커, 그리고 척추측만 환자를 층화하고 척추측만증이 발달할 위험을 예측하기 위한 이들의 용도
AU2014284075A1 (en) 2013-06-17 2016-01-07 Chu Sainte-Justine Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing GiPCR signaling in scoliotic subjects
KR20160020554A (ko) * 2013-06-17 2016-02-23 슈 생-쥐스땡 척추측만 개체의 세포에서 gipcr 신호전달을 증가시키는 방법
WO2015032005A1 (en) * 2013-09-09 2015-03-12 Chu-Sainte-Justine New marker for the classification, diagnosis and treatment of scoliosis
TWI745271B (zh) 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
CN106310610A (zh) * 2016-10-21 2017-01-11 上海交通大学医学院附属新华医院 一种脊柱侧凸特定运动疗法
CN106841593B (zh) * 2017-03-24 2018-08-17 北京致成生物医学科技有限公司 Lacc1和fhl2基因在制备脊柱侧弯检测产品中的应用
CN111638329B (zh) * 2020-06-09 2021-06-01 南方医科大学 一种用于检测布鲁氏菌病elispot检测试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
CA2164728A1 (en) * 1993-06-22 1995-01-05 Helmut Ponta Processes for diagnosing and analysing tumours
JPH10504828A (ja) 1994-08-30 1998-05-12 ハイアル ファーマスティカル コーポレイション 細胞活性調整のためのヒアルロン酸およびその誘導体
US5858709A (en) * 1996-10-15 1999-01-12 Smithkline Beecham P.L.C. Fibronectin binding protein B compounds
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
JP2005517379A (ja) 1999-01-18 2005-06-16 オステオミーター・ビオテク・エー／エス 遺伝的疾病素因
IL145851A0 (en) * 1999-04-15 2002-07-25 Childrens Medical Center Osteopontin-derived chemotactic and inhivitory agents and uses therefor
EP1269196B1 (en) 2000-03-23 2007-11-21 Glaxo Group Limited Method of screening for inhibitors of osteopontin
RU2305111C2 (ru) * 2001-09-25 2007-08-27 Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют Рекомбинантное антитело против остеопонтина и его применение
CA2373854A1 (en) 2002-02-28 2003-08-28 Alain Moreau Methods of diagnosing and counteracting adolescent idiopathic scoliosis
EP1532268A4 (en) * 2002-03-21 2006-07-05 Yissum Res Dev Co PERIPHERAL BLOOD CELL MARKERS SUITABLE FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS AND THESE USEFUL METHODS AND KITS
US20050282163A1 (en) * 2003-02-03 2005-12-22 Medstar Research Institute Washington Hospital Center Polymorphisms in elastin, fibrillin and related genes as predisposing to restenosis and to a therosclerosis
US20090104620A1 (en) * 2007-07-03 2009-04-23 Axial Biotech, Inc. Simplified Method of Determining Predisposition to Scoliosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANG, C. et al. BJU International, 2005, vol.96, pp803-805 *
BAGNALL, K. et al.: 'The effects of melatonin therapy on the development of scoliosis after pinealectomy in the chicken.' Journal of Bone and Joint Surgery, American volume, 1999, vol.81, no. 2, pp191-199. *
DASTYCH, M. et al.: 'Idiopathic Scoliosis and Concentrations of Zinc, Copper, and Selenium in Blood Plasma.' Biological Trace Element Research, 2002, vol.89, pp105- 110. *
MOR, G. et al. PNAS, 2005, vol 102, no. 21, pp7677-7682 *

Also Published As

Publication number Publication date
IL201186A0 (en) 2010-05-17
CA2682114A1 (en) 2008-10-09
US10073101B2 (en) 2018-09-11
HK1132550A1 (en) 2010-02-26
US20150323553A1 (en) 2015-11-12
AU2008234374A1 (en) 2008-10-09
US20100075333A1 (en) 2010-03-25
IL201186A (en) 2013-10-31
MX2009010400A (es) 2010-02-18
US20130266966A1 (en) 2013-10-10
WO2008119170A1 (en) 2008-10-09
KR20100016075A (ko) 2010-02-12
EP2132568A4 (en) 2010-06-09
JP2010522699A (ja) 2010-07-08
KR101436578B1 (ko) 2014-09-01
EP2132568B1 (en) 2013-05-29
CN101680887A (zh) 2010-03-24
CN101680887B (zh) 2014-06-25
JP5426530B2 (ja) 2014-02-26
CA2682114C (en) 2017-08-01
EP2132568A1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
EP2132568B1 (en) Method of determining risk of scoliosis
Loumaye et al. Biomarkers of cancer cachexia
Rutsch et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification
Yang et al. Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy
Radenkovic et al. Expanding the clinical and metabolic phenotype of DPM2 deficient congenital disorders of glycosylation
Fotis et al. Intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 in children. Do they play a role in the progression of atherosclerosis?
US20180171015A1 (en) Method of Increasing GIPCR Signalization in the Cells of a Scoliotic Subject
US20170248586A1 (en) Marker For Depression, Assay Method, Method For Determining Depression, Screening Method For Antidepressants, And Kit
Asif et al. T-786C Polymorphism of the nos-3 Gene and the Endothelial Cell Response to Fluid Shear Stress A Proteome Analysis
US20130029871A1 (en) Methods of stratifying adolescent idiopathic scoliosis, isolated nucleic acid molecules for use in same and kits using same
WO2014047442A2 (en) Biomarkers for assessing treatment of sialic acid deficiency diseases and conditions
EP3011332B1 (en) New markers for severe progression of idiopathic scoliosis and uses thereof to stratify scoliotic patients and predict the risk of developing scoliosis
US20160139146A1 (en) Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing gipcr signaling in scoliotic subjects
ES2896473T3 (es) Uso de SH3YL1 como marcador para el diagnóstico de nefropatía
HK1132550B (en) Method of determining risk of scoliosis
WO2010035888A1 (ja) マイクロドメイン病のバイオマーカー
Fusto Genetic and clinical modifiers in Duchenne muscular dystrophy
US20090048121A1 (en) Screening Method for the Early Diagnosis of Cerebral Vasospasm
US20080261910A1 (en) Diagnostic Methods Based on Polymorphisms of Glucosyltransferase-Like Protein
HK1132014B (en) Methods of stratifying adolescent idiopathic scoliosis, isolated nucleic acid molecules for use in same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired